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BACKGROUND AND PURPOSE
The chemokine receptor CXCR3 directs migration of T-cells in response to the ligands CXCL9/Mig, CXCL10/IP-10 and
CXCL11/I-TAC. Both ligands and receptors are implicated in the pathogenesis of inflammatory disorders, including
atherosclerosis and rheumatoid arthritis. Here, we describe the molecular mechanism by which two synthetic small molecule
agonists activate CXCR3.
EXPERIMENTAL APPROACH
As both small molecules are basic, we hypothesized that they formed electrostatic interactions with acidic residues within
CXCR3. Nine point mutants of CXCR3 were generated in which an acidic residue was mutated to its amide counterpart.
Following transient expression, the ability of the constructs to bind and signal in response to natural and synthetic ligands
was examined.
KEY RESULTS
The CXCR3 mutants D112N, D195N and E196Q were efficiently expressed and responsive in chemotaxis assays to CXCL11
but not to CXCL10 or to either of the synthetic agonists, confirmed with radioligand binding assays. Molecular modelling of
both CXCL10 and CXCR3 suggests that the small molecule agonists mimic a region of the ‘30s loop’ (residues 30–40 of
CXCL10) which interacts with the intrahelical CXCR3 residue D112, leading to receptor activation. D195 and E196 are
located in the second extracellular loop and form putative intramolecular salt bridges required for a CXCR3 conformation that
recognizes CXCL10. In contrast, CXCL11 recognition by CXCR3 is largely independent of these residues.
CONCLUSION AND IMPLICATIONS
We provide here a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. Such
findings may have implications for the design of CXCR3 antagonists.
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Introduction
Chemokines are low-molecular weight proteins that mediate
the migration of leucocytes. In humans, they constitute a
family of over 40 proteins, with the majority of chemokines
falling into one of two groups, namely the CC or CXC classes,
where the first two cysteine residues within the N-terminal
region are either adjacent or have a single amino acid sepa-
rating them (Zlotnik and Yoshie, 2000). Chemokines exert
their effects by binding to specific GPCRs expressed on the
leucocyte surface (Murphy et al., 2000; Murphy, 2002). The
signals transduced by these receptors help to coordinate leu-
cocyte trafficking and the establishment of lymphoid
microenvironments. Their discovery has greatly increased
our understanding of selective leucocyte recruitment to sites
of inflammation. Indeed, the excessive or inappropriate
release of chemokines has been linked with the pathogenesis
of several inflammatory diseases and a variety of autoim-
mune disorders (Charo and Ransohoff, 2006).
The chemokine receptor CXCR3 is expressed on the
surface of a substantial proportion of freshly purified T-cells
(Loetscher et al., 1996), is up-regulated upon polarisation to
the Th1 subset (Loetscher et al., 1998; Meiser et al., 2008) and
binds the chemokines CXCL9/Mig, CXCL10/IP-10 and
CXCL11/I-TAC with nanomolar affinities (Cole et al., 1998;
Weng et al., 1998; receptor and ligand nomenclature follows
Alexander et al.; 2011). All three CXCR3 ligands are induced
by IFN-g and therefore thought to promote Th1 immune
responses (Luster and Ravetch, 1987; Farber, 1990; Cole et al.,
1998;), notably in the pathogenesis of several clinically
important inflammatory disorders, including rheumatoid
arthritis and atherosclerosis (Tsubaki et al., 2005; Kwak et al.,
2008). As GPCRs are inherently ‘druggable’, accounting for
40% of all prescribed drugs (Fredriksson et al., 2003), block-
ade of CXCR3 by small molecules may suggest alternative
therapeutic approaches to treat inflammation and several
prototypic antagonists of CXCR3 have been described in the
literature (Pease and Horuk, 2009). Consequently, much
effort has been undertaken to understand the events under-
lying CXCR3 activation. The chemokines CXCL10 and
CXCL11 have distinct potencies and efficacies in a variety of
assays, including internalization and cell migration (Xanthou
et al., 2003; Colvin et al., 2004; 2006; Dagan-Berger et al.,
2006), suggesting that they interact with CXCR3 in different
ways and are likely to stabilize different conformations of the
receptor. Previous work by ourselves and others has high-
lighted domains of CXCR3 implicated in ligand binding and
receptor activation, notably the second extracellular loop
(ECL) (Xanthou et al., 2003; Colvin et al., 2006). In this study,
we used recently described small molecule agonists of CXCR3
to probe the structure–function relationships of ligands and
receptor, and to identify key residues required for activation
of CXCR3 by CXCL10 and small-molecule mimetics of
CXCL10.
Methods
Generation of receptor mutants and their
transient expression in the murine pre-B cell
line L1.2
Previously described pcDNA3 plasmids containing human
wild-type (WT) CXCR3 cDNA with an HA epitope tag
encoded at the N terminus (Meiser et al., 2008) were used as
a template for the generation of point mutants by PCR using
the QuikChange II site-directed mutagenesis kit (Stratagene,
Amsterdam, the Netherlands). All constructs were verified
by DNA sequencing (Eurofins MWG Operon, Ebersberg,
Germany) before use. L1.2 cells were transiently transfected
by electroporation with 1 mg of vector DNA per 106 cells at
330 V, 975 mF and incubated overnight in medium supple-
mented with 10 mM of sodium butyrate to enhance gene
expression.
Flow cytometry. Cell surface expression of CXCR3 was
assessed by flow cytometry after staining with either mouse
anti-human CXCR3 mAb or an anti-HA antibody and FITC-
conjugated secondary antibody as described previously
(Vaidehi et al., 2009). Expression was analysed using a FACS-
Calibur flow cytometer (Becton Dickinson, Mountain View,
CA, USA). Data are presented as a percentage of the amount
of WT CXCR3 expressed in control transfectants.
Chemotaxis assay. Assays of chemotactic responsiveness
were carried out as previously described (Vaidehi et al., 2009)
using 96-well ChemoTx® plates with 5 mm pores (Neuro-
probe, Gaithersburg, MD, USA). Migrating cells were detected
by the use of CellTiter Glo® Dye (Promega, Southampton,
UK) and resulting luminescence measured using a TopCount
scintillation counter (Perkin Elmer, Waltham, MA, USA).
Basal migration of cells to buffer alone was subtracted from
the resulting data, with individual results expressed as a per-
centage of the total cells applied to the filter. In all experi-
ments, each data point was assayed in duplicate. In every
experiment, cells transiently expressing WT CXCR3 were
employed as a positive control.
Radiolabelled chemokine binding studies. Whole-cell binding
assays on transiently transfected L1.2 cells were performed as
described previously (Vaidehi et al., 2009) using 0.1 nM 125I-
CXCL10 or 125I-CXCL11 (Perkin Elmer) and increasing con-
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centrations of unlabelled chemokine or antagonist. Cell-
associated radioactivity was counted in a Canberra Packard
Cobra 5010 gamma counter (Canberra Packard, Pange-
bourne, UK). Curve fitting and subsequent data analysis was
carried out using the program PRISM (GraphPad Software,
Inc., La Jolla, CA, USA) and IC50 values were obtained by
nonlinear regression analysis. In all experiments, each data
point was assayed in duplicate. Background binding levels
obtained in the presence of a 1000–3000 molar excess of
unlabelled chemokine were subtracted from each data point
and data are presented as the percentage of counts obtained
in the absence of competing ligand. Kd values were calculated
from homologous binding curves prepared in GraphPad
Prism using the equation:
Total binding
B Hot
Hot Cold
NSB=
[ ]
[ ] + [ ] + +
max ,
Kd
where Bmax refers to the total ligand binding, [Hot] and
[Cold] refer to the concentrations of labelled and unlabelled
ligands, respectively, and NSB refers to non-specific binding.
Three-dimensional alignments of CXCL10
with small molecule CXCR3 agonists
This was carried out using a novel multiple ligand alignment
method as previously described (Anghelescu et al., 2008).
Visualization of the CXCL10 crystal structure (Booth et al.,
2002) was carried out using PyMol (DeLano, 2002), using
structure 1LV9 from the Protein Data Bank (http://
www.rcsb.org/pdb/home/home.do).
Modelling CXCR3 interactions with small
molecule agonists
The three-dimensional model of the seven helical transmem-
brane bundle of human CXCR3 was predicted using the ab
initio method MembStruk (Vaidehi et al., 2002; 2009). The
extra- and intracellular loops were added using the method,
Modeller (Fiser et al., 2000). In ECLs 2 and 3, we observed that
the residues D195, R216, E196 and K125 were in proximity
and therefore performed constrained minimization to bring
the pairs of residues together to form salt bridges. The small
molecules compounds 1 and 3 were built using the LigPrep
module from the Schrodinger Glide suite (Schrodinger Inc.,
San Diego, CA, USA). Multiple ligand conformations were
generated for the two compounds and docked using Glide XP
(Schrodinger Inc). Next, a short energy minimization was
performed on each docked pose and the binding energy of
this optimized pose was calculated. The binding energy was
calculated as BE (binding energy) = PE (ligand in fixed
protein) – PE (ligand in solvation), where BE is the binding
energy and PE is the potential energy. The compound poses
were then sorted by binding energy and the top 20 confor-
mations inspected visually to maximize the interactions with
residues that are known to interact with ligands in chemok-
ine receptors (Vaidehi et al., 2009).
Data analysis. Data are expressed as the mean  SEM of at
least three separate experiments, and were analysed with a
relevant statistical test, as stated, using PRISM v4.03 software.
Materials
Reagents were purchased from Invitrogen (Paisley, UK),
unless stated otherwise. Recombinant human CXCL10 and
CXCL11 were purchased from PeproTech EC Ltd (London,
UK). The mouse anti-human CXCR3 mAb (clone 49801.111)
and the mouse isotype-matched control IgG1 (MOPC 21
clone) were obtained from Sigma-Aldrich (Poole, UK). The
monoclonal mouse anti-haemagglutinin (HA) anti-HA.11
antibody was from Covance (Berkeley, CA, USA) and its cor-
responding IgG1 isotype control antibody from Sigma-
Aldrich. The murine pre-B cell line L1.2 was maintained as
described previously (Vaidehi et al., 2009) in suspension
at 37°C with 5% CO2 at a density of no more than
1 ¥ 106 cells·mL-1. The human lymphoma cell line H9
[Repository # 0001] was obtained from the Programme EVA
Centre for AIDS Reagents, National Institute for Biological
Standards and Control, Potters Bar, UK, supported by the EC
FP6/7 Europrise Network of Excellence, AVIP and NGIN con-
sortia and the Bill and Melinda Gates GHRC-CAVD Project
and was donated by Dr R. Gallo, University of Maryland
School of Medicine. H9 cells were maintained in suspension
in RPMI medium supplemented with 10% FBS at 37°C with
5% CO2 at a density of no more than 1 ¥ 106 cells·mL-1.
Results
Compounds #1 and #3 are partial agonists
of CXCR3
Stroke et al. (2006) previously reported the identification of
two small molecule agonists of CXCR3 named compound #1
(Cp#1) and compound #3 (Cp#3). Both small molecules share
a similar chemical structure consisting of an N-containing
bicyclic unit, a hydrophobic group and a basic amino acid
(Figure 1A). In the first instance, we assessed the agonistic
activities of Cp#1 and Cp#3, in chemotactic assays using the
human lymphoblast line H9 (which expresses endogenous
CXCR3) and previously described murine L1.2 WT CXCR3-
transfectants (Xanthou et al., 2003). Both compounds
induced typically bell-shaped chemotactic responses in either
cell line, with 100 nM–1 mM of either small molecule induc-
ing an optimal response. Both Cp#1 and Cp#3 were partial
agonists compared with the natural ligands CXCL11 and
CXCL10, which exhibited more potent and efficacious
responses as previously reported (Stroke et al., 2006)
(Figure 1B and C). Notably, Cp#1 and Cp#3 were an order of
magnitude more potent in H9 cells, compared with CXCR3
transfectants, which may reflect their ability to induce more
efficient coupling of CXCR3 to human G proteins or that
CXCR3 expression levels were higher in this cell line.
Disparate binding sites on CXCR3 for
CXCL10 and CXCL11
Previous studies have described CXCL10 and CXCL11 as
allosteric ligands of CXCR3, based on their respective abilities
in heterologous competition binding assays. While CXCL11
is reported to completely displace CXCL10 from the receptor,
a considerable proportion of bound CXCL11 is not displaced
by CXCL10 (Cox et al., 2001; Xanthou et al., 2003). To
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examine the activity of the compounds further, we subjected
L1.2 transfectants expressing WT CXCR3 to heterologous
competition assays using 125I-CXCL10 and 125I-CXCL11
(Figure 2A and B). Radiolabelled CXCL10 was readily dis-
placed from cells by CXCL11, CXCL10 and Cp#3 (respective
IC50 values of 0.4 nM, 2.0 nM and 3.0 nM) while Cp#1 was
unable to compete for more than 25% of the radiolabel. In
the reciprocal experiment, 125I-CXCL11 was readily displaced
by unlabelled CXCL11 (IC50 values of 1.2 nM) but was resis-
tant to increasing concentrations of either CXCL10 or the
two small-molecule agonists, which were unable to displace
more than 50% of the 125I-CXCL11. This suggests that Cp#1
and Cp#3 mimic CXCL10 with respect to ligand binding and
that CXCL10 and CXCL11 are allosteric ligands of CXCR3.
The second ECL of CXCR3 is critical for
agonist function
Previous work by ourselves using chimaeric CXCR1/CXCR3
receptors suggested a multisite model for the interaction of
CXCR3 with its ligands in which multiple extracellular
domains are required for chemokine binding and receptor
activation, notably the second and third ECLs of CXCR3
(Xanthou et al., 2003). To assess whether the small molecule
agonists activated CXCR3 in a similar fashion, we used two
chimeric constructs from our previous study where the
Figure 1
Basic small molecules are partial agonists of CXCR3. (A) The chemical
structures of Cp#1 and Cp#3. The chemotactic responses of (B) the
L1.2 CXCR3 transfectants and (C) the human lymphoblast cell line
H9 to increasing concentrations of CXCL10, CXCL11, Cp#1 and
Cp#3.
Figure 2
Small molecule agonists of CXCR3 mimic CXCL10 in their ability to
displace CXCR3 ligands from their receptor. The relative abilities of
unlabelled CXCL10, CXCL11, Cp#1 or Cp#3 to displace 125I-CXCL10
(A) or 125I-CXCL11 (B) from WT CXCR3 transfectants in heterologous
competition assays.
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second and third ECLs of CXCR3 were exchanged with the
corresponding regions of CXCR1 to generate the constructs
Chi-7 and Chi-8 respectively (Figure 3A). Both ECL2 and
ECL3 share limited sequence homology (16 and 23% identity
respectively). Both Chi-7 and Chi-8 were transiently
expressed as detected by flow cytometry (data not shown).
The chemotactic responses of the L1.2 transfectants to
increasing concentrations of Cp#1 and Cp#3 were compared
with that of WT-CXCR3. Replacement of ECL2 of CXCR3
with that of CXCR1 (Chi-7) resulted in a loss of chemotactic
responses to both Cp#1 and Cp#3 (Figure 3B and C), while
the replacement of ECL3 (Chi-8) markedly reduced the effi-
cacy of the chemotactic responses compared with WT-CXCR3
transfectants but did not ablate them. Thus, as is the case for
the natural agonists, ECL2 and ECL3 of CXCR3 appear impor-
tant for functional responses to synthetic agonists.
Small molecule agonists of CXCR3 appear to
mimic a portion of the ‘30s loop’ (residues
30-40) of the natural ligand CXCL10
We subsequently compared the structure of Cp#1 and Cp#3
with the natural CXCR3 agonists CXCL10 and CXCL11. As
the tetrahydroisoquinoline ring in Cp#1 imposes conforma-
tional restraints similar to proline residues in peptide chains,
the amino acid sequences of CXCR3 ligands were searched for
candidate sequences containing a Pro-Arg-X or Pro-Lys-X
motif (X corresponding to a hydrophobic residue). One such
five-residue sequence of CXCL10, spanning amino acid resi-
dues 35–39 of CXCL10 (Phe-Cys-Pro-Arg-Val), matched these
requirements and the coordinates for these atoms were taken
from the previously solved NMR structure of CXCL10 (Booth
et al., 2002). Keeping the atomic coordinates of the CXCL10
atoms fixed, there was an attempt to align both compounds
to the peptide sequence of CXCL10 but only Cp#1 was suc-
cessfully aligned (Figure 4A), revealing obvious structural
similarities with the ‘30s loop’ region of CXCL10, which
connects the first two strands of the anti-parallel b-pleated
sheet. (Figure 4B).
Biological responses to CXCL10 but not
CXCL11 are susceptible to mutation of acidic
residues in the second transmembrane helix
and the second ECL
Examination of the CXCR3 primary sequence highlighted
seven acidic residues within CXCR3, which we postulated
might act as counter-ions to the basic moieties of Cp#1 and
Cp#3 (Figure 4C). To test this hypothesis, point mutagenesis
of these acidic residues was undertaken, generating a panel of
seven mutant cDNA constructs in which each acidic residue
(aspartate or glutamate) was mutated to its amide counterpart
(asparagine or glutamine). Transient transfection of all seven
constructs suggested that they were expressed at levels not
significantly different from that of WT CXCR3 (Figure 5A,
Table 1). The same transfectants were initially subjected to
homologous competition radiolabelled binding, using either
0.1 nM 125I-CXCL11 (Figure 5B) or 0.1 nM 125I-CXCL10
(Figure 5C) and a single 1000-fold excess of unlabelled ligand.
125I-CXCL11 binding was robust among all mutants, except
for the D112N mutant, which bound 125I-CXCL11 at detect-
able but significantly reduced levels (Figure 4B) compared
Figure 3
The ECL2 of CXCR3 appears critical for small molecule agonist func-
tion. (A) The structure of previously described CXCR3 chimeras con-
taining ELC2 or ECL3 from CXCR1. The chemotactic responses of
L1.2 transfectants expressing WT CXCR3 or chimeric constructs to
increasing concentrations of Cp#1 (B) and Cp#3 (C).
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Figure 4
Small molecule agonists of CXCR3 appear to mimic the ‘30s loop’ of
the natural ligand CXCL10. (A) The alignment of a five-residue
sequence of CXCL10 spanning amino acid residues 35–39 (Phe-Cys-
Pro-Arg-Val) with Cp#1. CXCL10 is depicted in grey and is overlaid
with Cp#1 (cyan). (B) Modelling of the CXCL10 crystal structure,
with the pertinent side chains in the ‘30s loop’ highlighted.
(C) Acidic residues in CXCR3 (filled circles) mutated to their amide
counterpart.
Figure 5
CXCL10 but not CXCL11 binding is susceptible to mutation of D112,
D195 and E196 residues in CXCR3. (A)The relative expression pro-
files of mutant CXCR3 constructs compared with WT CXCR3. Spe-
cific binding of 125I-CXCL11 (B) or 125I-CXCL10 (C) to the mutant
CXCR3 constructs.
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with WT CXCR3. In contrast, 125I-CXCL10 binding was
extremely sensitive to mutation, with several mutants dis-
playing significantly reduced ligand binding, notably the
D112N, D195N and E196Q mutants (Figure 5C). Homolo-
gous competition assays employing a series of unlabelled
ligand concentrations were subsequently used to determine
the relative affinity of each ligand for the mutants (Figure 6A
and B and Table 1).
D112, E195 and E196 of CXCR3 are
specifically required for receptor activation by
CXCL10 but not CXCL11
We subsequently examined the activities of each CXCR3
mutant in chemotaxis assays, examining migratory
responses to increasing amounts of CXCL11, CXCL10, Cp#1
or Cp#3 (Figure 7A–D). In keeping with the 125I-CXCL11
binding data, all of the CXCR3 mutants allowed cells to
migrate in a dose-dependent fashion in response to CXCL11
(Figure 7A), with optimal chemotaxis for the majority of
constructs observed at 30 nM, identical to that of WT
CXCR3 transfectants. The CXCL11-mediated responses of
D282N, E293Q and D297N were shifted to the right, sug-
gesting that these residues play a role in receptor activation
by CXCL11. In the case of the D297N construct, the
reduced potency of CXCL11 in chemotaxis assays correlated
with a significant decrease in affinity for CXCR3, compared
with WT CXCR3 (Kd of 10.9 nM cf. Kd of 26.3 nM). The
majority of CXCR3 mutants also responded to CXCL10 in
the same manner as WT CXCR3, exhibiting the bell-shaped
dose-response curve typical of these assays, with a
maximum response to 30 nM CXCL10 (Figure 7B). Unlike
the robust CXCL11 responses, chemotaxis to CXCL10 was
significantly impaired for several mutants. Notably, cells
expressing the D112N, D195N and E196Q mutants were
unresponsive to CXCL10. In the main, this correlated with
a decreased ability to bind 125I-CXCL10, although for the
D195N mutant, the affinity was almost identical to that of
WT CXCR3, suggesting that D195 is critical for receptor
activation but not binding of CXCL10. As was the case for
CXCL10, transfectants expressing the D112N, D195N and
E196Q mutants were also unresponsive to Cp#1 (Figure 7C)
and Cp#3 (Figure 7D), suggesting that with respect to their
biological activity, the compounds mimic CXCL10.
Table 1
Expression, chemotaxis and binding properties of CXCR3 mutants
Construct
% of WT CXCR3
surface expression
% of WT chemotaxis
to 30 nM CXCL11
% of WT chemotaxis
to 30 nM CXCL10
KD CXCL11
binding (nM)
KD CXCL10
binding (nM)
WT CXCR3 100 100 100 10.9  5.6 4.7  0.5
D112N 76.8  7.6 80.2  24.5 17.8  1.5*** 3.8  0.7 ND
D195N 74.2  2.1 90.3  19.7 14.7  3.9** 16.0  3.4 4.7  1.1
E196Q 188.0  79.9 76.0  18.9 9.5  4.1** 0.4  0.1 7.6  3.4
D278N 92.6  1.4 80.7  27.6 49.3  5.9* 2.6  1.0 30.9  3.2*
D282N 62.1  26.9 87.5  17.5 84.2  18.9 1.4  0.2 2.9  1.3
E293Q 134.8  16.8 77.6  23.1 49.8  4.4** 3.7  0.9 1.2  0.0*
D297N 90.2  10.4 44.1  6.1* 72.9  25.7 26.3  0.5* 7.1  0.5*
Surface expression and chemotaxis are expressed relative to values obtained for transfectants expressing WT CXCR3. ND indicates not
determined. The mean values  SEM from at least three experiments are shown. ***P < 0.001, **P < 0.01 and *P < 0.05, significantly different
from corresponding values for the WT CXCR3; Student’s t-test.
Figure 6
Mutation of several acidic residues in the first and second ECLs of
CXCR3 significantly increases affinity for CXCL11 but not for CXCL10.
The relative abilities of increasing concentrations of unlabelled ligand
to displace 0.1 nM 125I-CXCL11 (A) or 0.1 nM 125I-CXCL10 (B) in
homologous competition assays using CXCR3 transfectants.
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To assess the effects of the D112N, D195N and E196Q
mutations on the ligand binding sites of Cp#1 and Cp#3, we
examined the ability of the compounds to displace 125I-
CXCL10 from transfectants expressing the mutant con-
structs, albeit with some experimental limitations. Firstly,
125I-CXCL11 was omitted from these experiments as we had
previously shown that neither compound was able to effec-
tively displace the radioligand (Figure 2B). Secondly, the
D112N mutation was omitted from these experiments as this
construct was unable to effectively bind CXCL10 (Figure 6B).
Thirdly, the significant drop in Bmax for 125I-CXCL10 binding
at the D195N and E196Q mutants, coupled with the rela-
tively poor ability of Cp#1 to displace 125I-CXCL10, leads us to
omit Cp#1 from these experiments. This left us with experi-
mental determination of the relative Kd values for Cp#3 at
cells expressing WT CXCR3 and the D195N and E196Q vari-
ants (Figure 7E). While the D195N mutant behaved essen-
tially as WT CXCR3 in these assays (EC50 values of 3.2 nM and
8.2 nM respectively), the ability of Cp#3 to displace 125I-
CXCL10 from cells expressing the E196Q mutant was signifi-
cantly impaired, with less than 50% of the radiolabel
displaced with a 3000-fold molar excess of Cp#3.
Discussion and conclusions
Current models of chemokine receptor activation are based
predominantly on the two-step model of receptor activation,
in which the chemokine is initially tethered by the receptor
N-terminus and orientated such that key regions of the
chemokine can then make productive interactions with other
regions of the receptor (Monteclaro and Charo, 1996; Pease
et al., 1998). Several studies have implicated the N-terminus
and ‘30’s loop’ regions of chemokines as playing critical roles
in receptor activation, with truncation and mutation of
either chemokine domain typically resulting in a loss of activ-
Figure 7
Mutation of D112, D195 and E196 in CXCR3 abolishes chemotaxis to CXCL10 and small molecule CXCL10 mimetics but has little effect on
CXCL11 responses. The relative abilities of WT and mutant CXCR3 transfectants to migrate in response to increasing concentrations of CXCL11
(A), CXCL10 (B), Cp#1 (C) and Cp#3 (D) in chemotaxis assays. Panel E shows the relative abilities of increasing concentrations of Cp#3 to displace
125I-CXCL10 from transfectants expressing WT CXCR3 or the mutant constructs D125N and E196Q.
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ity (Clark-Lewis et al., 1994; Crump et al., 1997; Gong and
Clark-Lewis, 1995; Jarnagin et al., 1999). The discovery of
small molecule agonists of chemokine receptors has allowed
us to bypass the N-terminal tethering event and ask questions
about which residues of the receptor are involved in activa-
tion. We describe here the characterization of two small mol-
ecule agonists of CXCR3, Cp#1 and Cp#3, which activate
CXCR3 by binding to an intrahelical pocket. Such com-
pounds are currently under investigation as potential thera-
pies for transplant rejection, where the desensitization of
CXCR3 may be envisaged to dampen the recruitment of
T-cells to the allograft (O’Boyle et al., 2010) or as agents for
promoting bone marrow regeneration following chemo-
therapy (Han et al., 2010).
In the case of Cp#1, it appears that the activity of the
molecule results from its ability to successfully mimic the ‘30s
loop’ of the natural chemokine agonist, CXCL10. This is
supported by alignment of the small molecule agonists with
the solution structure of CXCL10, with Cp#1 mimicking the
Pro-Arg-Val sequence, formed by residues 37–39 within the
‘30s loop’ region of the chemokine. Lending credence to our
findings, Arg-38 is one of several CXCL10 residues reported to
undergo a conformational change upon binding of the
chemokine to a peptide corresponding to the CXCR3
N-terminus (Booth et al., 2002). Collectively, our data is remi-
niscent of studies of the urotensin receptor in which a pep-
tidomimetic was generated from the Trp-7, Lys-8 and Tyr-9
triplet of urotensin (Flohr et al., 2002) and supports the
notion that virtual screening of pharmocophores comprising
the ‘30s loop’ region of chemokines could be a general strat-
egy for the identification of compounds with agonist activity.
We have identified three residues of CXCR3 that were
critical for receptor activation by Cp#1 and Cp#3, namely
D112, D195 and E196. Of significance was our finding that
mutation of these three acidic residues ablated responses to
CXCL10 but not responses to CXCL11. This suggests that
D112, D195 and E196 of CXCR3 are required to bind and be
activated by CXCL10, resulting in productive signalling, as
measured by chemotaxis. In contrast, mutation of D112,
D195 and E196 does not preclude binding and stabilization
of an active CXCR3 conformation by CXCL11. Interestingly,
the equivalent of the Pro-Arg-Val sequence of the ‘30s loop’
region of CXCL11 is Asp-Lys-Ile, suggesting that in order to
activate CXCR3, the basic charge at this position has to be in
the context of the conformational restraints imposed by
Pro-37 in CXCL10 or the tetrahydroisoquinoline ring found
in Cp#1.
Combining our experimental data with ab initio model-
ling of CXCR3, we find that D112 is located at the extracel-
lular end of the transmembrane helix 2, (TM2) and acts as a
counter-ion for the arginine moiety of the small molecules
(Figure 8A and B), which mimics the interaction of Arg-38 of
the natural ligand CXCL10 with the receptor. Previous
mutagenesis of D112 to lysine or alanine was reported to
Figure 8
Ab initiomodelling of CXCR3. (A) and (B) Top views of a model of human CXCR3 predicted using MembStruk showing the small molecule agonists
Cp#1 (A) and Cp#3 (B) residing in a binding site predicted using Glide XP. In both models, D112 acts as a counter-ion for the basic moiety of
either compound, with a predicted cluster of predominantly hydrophobic residues interacting with the ligand in the binding site. Numbers in
parenthesis refer to the TM helix (1–7) in which the residue resides. (C) Comparison of the binding site of the compound called ‘1t’ in the CXCR4
crystal structure (pink) to the predicted binding site of Cp#3 in CXCR3 (cyan) shows that the two compounds bind in similar locations in their
respective receptors. (D) The two predicted salt bridges within the extracellular domains of CXCR3 between K125 (ECL1) and D196 (ECL2) and
between R288 (ECL3) and D195 (ECL2).
BJP B Nedjai et al.
920 British Journal of Pharmacology (2012) 166 912–923
result in a loss of both CXCL10 and CXCL11 binding and
chemotactic responses to both ligands (Colvin et al., 2006).
Here, we show that mutation of D112 to asparagine, which
preserves some features of the aspartate side chain but loses
the negative charge, results in a selective loss of CXCL10
binding and chemotactic response. Comparison of the
binding site of the compound called ‘1t’ in the CXCR4 crystal
structure (Wu et al., 2010) to the predicted binding site of
Cp#3 in CXCR3 shows that the two compounds bind in
similar locations in their respective receptors (Figure 8C).
However, as Cp#3 is larger than 1t, its binding site extends
more towards TM1 and TM7, as shown in Figure 8C. The
CXCR4 crystal structure reveals a severely tilted TM3 that is
not observed in our model of CXCR3. The tilt accounts for
the differences in the respective position of the ligands in our
model.
D195 and E196 are located within the second ECL (ECL2),
a region of CXCR3 that ourselves and others have previously
shown to be critical for activation of CXCR3 (Xanthou et al.,
2003; Colvin et al., 2006). Modelling of the ECLs (Figure 8D)
suggests that these residues form putative intermolecular salt
bridges that stabilize CXCR3 and presumably gate entry of
the ligand into the binding pocket as has been previously
shown for the b2-adrenoceptor (Wang and Duan, 2009). In
our model, D195 and E196 of ECL2 form salt bridges with
R288 of ECL3 and K125 of ECL1 respectively. It is noteworthy
that when we previously characterized the Chi-8 construct in
which ECL3 of CXCR3 was replaced by the corresponding
region of CXCR1 (Figure 3A), although CXCL11 binding was
well preserved, CXCL10 binding was abolished (Xanthou
et al., 2003). With reference to our model described here, we
can now attribute the lack of CXCL10 binding to the loss of
the salt bridge between D195 and R288, as a glutamate
residue (E275) is found in the analogous position within the
ECL3 of CXCR1.
The contrasting binding profiles of CXCL10 and CXCL11
in heterologous competition assays (Figure 2A and B) coupled
with the mutagenesis of D112, D195 and E196, which abol-
ished CXCL10, but not CXCL11, function, provide more
detailed information regarding the previous observation that
the two chemokines are allosteric ligands of CXCR3 (Cox
et al., 2001). How the two ligands interact with CXCR3 is
undoubtedly more complex than a simple allosteric mode of
binding in which both chemokines would displace each
other to a similar degree. One possible explanation is that
CXCL11 binds to a population of CXCR3 molecules, which is
inaccessible to CXCL10, perhaps higher order oligomers of
CXCR3 or receptors pre-coupled to intracellular molecules.
Alternatively, CXCL10 and CXCL11 may stabilize distinct
receptor conformations. This raises the possibility that the
two chemokines may induce ligand-selective bias at CXCR3
(Kenakin 2011) with the different CXCR3 conformations sta-
bilized by either ligand coupling to distinct intracellular sig-
nalling pathways. In this study our readout of biological
activity was chemotaxis, which is the final downstream func-
tion of CXCR3 activation and may be attained by several
signalling pathways. To further examine such possibilities,
pathway-specific assays would need to utilized.
Ligand binding data similar to that shown here has been
published regarding the binding of another pair of chemok-
ine agonists, CCL5 and CCL3, at the same CC chemokine
receptor, CCR1 (Jensen et al., 2008). This raises an interesting
question as to whether there is an evolutionary benefit to be
able to activate signalling pathways via distinct chemokine
receptor conformations. The promiscuous nature of many
chemokines (activating several different receptors) has led to
the proposition that the apparent redundancy in the system
affords a host the possibility of mounting robust immune
responses in the face of pressure from microorganisms (Man-
tovani, 1999). As pathogens are known to produce chemok-
ine mimetics, which can directly antagonize chemokine
receptors (Damon et al., 1998; Luttichau et al., 2000), it may
be beneficial for a host to be able to activate receptors by
distinct mechanisms, enhancing the prospects that at least
one cognate ligand may signal under conditions of biological
duress. From a pharmacological perspective, it raises the
intriguing possibility that specific compounds could be devel-
oped, which block the activation of an undesirable signalling
pathway at a single chemokine receptor but leave intact the
ability to activate a desirable signalling pathway. In therapeu-
tic terms, such molecules would serve to dampen down
an inflammatory response without compromising host
immunity.
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